Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.

Cancer Immunol Immunother · 2023 · PMC10198838 · PMID 36602564

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a marginal trendno p-value reported

We found no significant changes in basal glycolysis although there was a marginal trend toward inhibition.

also in 111 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.